王拥军院士团队TASTE-2研究登上《英国医学杂志》脑细胞保护剂联合取栓显著降低致残

Core Insights - A significant advancement in stroke treatment has been achieved in China, with the TASTE-2 clinical study led by a team from Beijing Tiantan Hospital, confirming the efficacy of the innovative drug Daravone Dexborneol in improving functional independence in acute ischemic stroke patients [1][5][7] Group 1: Study Overview - The TASTE-2 study is a large-scale, randomized, double-blind clinical trial involving 1,362 patients across 106 centers in China, focusing on the efficacy of Daravone Dexborneol in conjunction with standard endovascular thrombectomy (EVT) [5][6] - The primary objective was to assess the functional independence of patients at 90 days post-treatment, measured by the modified Rankin Scale (mRS) [5][6] Group 2: Key Findings - Results showed that 55.0% of patients in the Daravone Dexborneol group achieved functional independence compared to 49.6% in the placebo group, indicating a statistically significant improvement (P=0.047) [6][7] - Subgroup analysis revealed that patients with mismatched imaging and clinical symptoms at admission benefited even more from the treatment, with a functional independence rate of 55.5% versus 42.9% in the placebo group [6][7] Group 3: Implications for Stroke Treatment - The study highlights a shift in stroke treatment paradigms from solely relying on "time windows" to a more precise "tissue windows" assessment, suggesting that combining neuroprotective agents with reperfusion therapy could yield significant benefits [6][7][8] - The findings are expected to influence future stroke treatment standards, emphasizing the importance of both "revascularization" and "neuroprotection" in comprehensive treatment strategies [7][8]